Biomarkers and Osteosarcoma and IGF
Bone and soft-tissue sarcomas tend to present in young adults. A wide variety of serological markers have been associated with osteosarcoma. Tumor markers involved in angiogenesis, cell adhesion, apoptosis, and the cell cycle have been shown to play an important role in osteosarcoma growth, differentiation, and metastasis. However, there are no universal and specific serum tumor markers for early diagnosis of osteosarcoma and primary screening in risk groups. There is strong empirical evidence that the IGF signal transduction pathway may be important in osteosarcoma. Several patents of IGF and molecular biomarkers/panels in osteosarcoma have been reported. The tissue/serum biomarker panels using high-throughput technology molecular signatures will have a role in early detection of the disease and noninvasive testing.
No Supplementary Data
No Article Media
Document Type: Research Article
Publication date: September 1, 2013
More about this publication?
- Recent Patents on Biomarkers publishes review and research articles, and guest edited thematic issues on important recent patents on biomarkers. The coverage includes novel biomarkers in basic, medical, environmental, and pharmaceutical research. A selection of important and recent patents on biomarkers is also included in the journal. The journal is essential reading for all researchers involved in biomarker research and discovery. The journal also covers recent research (where patents have been registered) in fast emerging patent biomarker applications; discovery and validation are covered for drug discovery, clinical development and molecular diagnostics.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites